资讯
20 天
Pharmaceutical Technology on MSNEMA to review GSK’s Nucala for COPD treatment expansionThe European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary disease ...
Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果